Modern surgery for liver metastases

Lodge, J. Peter A.

doi:10.1102/1470-7330/00/010077+09

Cited by 10 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these patients, chemotherapy is the method of choice. For a few malignancies, resection of liver metastases has been shown to improve the survival of the patients [1]. Colorectal cancer is one of a few malignant tumours in which the presence of limited synchronous liver metastases (i.e.…”

Section: Introductionmentioning

confidence: 99%

“…Based on the number and localization of the liver metastases and considering all other clinical parameters of the patient, only about 30% of colorectal patients with liver metastases may undergo resection. However, the 5-year survival of these patients is between 30% and 48% in comparison to a survival of less than 5% of patients with liver metastases not amenable to liver surgery [1–4]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liver metastases of colorectal cancer: US, CT or MR?

Schima

Kulinna²,

Langenberger³

et al. 2005

Cancer Imaging

View full text Add to dashboard Cite

In contrast to other extrahepatic malignancies many colorectal cancers can be cured even when there is metastatic spread to the liver. The diagnosis of liver metastases relies totally on imaging to decide which patients may be surgical candidates. The diagnostic value of ultrasound with contrast agents, multidetector CT and MR imaging with non-specific gadolinium chelates and liver-specific contrast agent is discussed. Nowadays MDCT is the mainstay of staging and follow-up of these patients, because it provides good coverage of the liver and the complete abdomen and the chest in one session. MR imaging has been shown to be superior to helical CT in the preoperative assessment of colorectal liver metastases. Large studies are needed to define the role of MDCT vs. MRI staging in patients referred for resection of liver metastases.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Liver metastases of colorectal cancer: US, CT or MR?

Schima

Kulinna²,

Langenberger³

et al. 2005

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…Surgical resection provides the best opportunity for long-term survival and is the only potentially curative treatment for CRLMs in selected groups, the 5-year median survival has been reported up to 58% [4] . Patients with untreated but potentially resectable metastases show a median survival of 8 months and the 5-year survival rate less than 5% [5][6] . Eligibility for surgical treatment requires strict criteria.…”

Section: Introductionmentioning

confidence: 99%

Ultrasound Examination in Detection and Characterization of Colorectal Liver Metastases

Qin¹,

Liu²

2015

International Journal of Radiology

View full text Add to dashboard Cite

The detection and characterization of colorectal liver metastases (CRLMs) depend firstly and totally on imaging studies. Transabdominal ultrasound (US) is the most cost-effective and readily available modality to screen the liver. Contrast-enhanced ultrasound (CEUS) has shown high performance comparable to contrast-enhanced computed tomography and magnetic resonance imaging in detection and characterization of CRLMs. Intraoperative ultrasonography (IOUS) is the golden standard for detection of CRLMs and frequently used for intraoperative decision making. This review illustrates the findings on ultrasonic examinations (including US, CEUS and IOUS) of CRLMs with an emphasis on unique capability and appropriate indications of ultrasonic examinations in the detection and characterization of CRLMs. We aim to highlight the advan¬tages of ultrasonic examinations, as well as underscoring potential pitfalls and limitations.

show abstract

Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging

Channual¹,

Pahwa

Lu³

et al. 2016

Abdom Radiol

View full text Add to dashboard Cite

Gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is a unique hepatocyte-specific contrast agent approved for clinical use in the United States in 2008. Gd-EOB-DTPA-enhanced MR has shown to improve detection and characterization of hepatic lesions. Gd-EOB-DTPA is now being routinely used in daily clinical practice worldwide. Therefore, it is important for radiologists to be familiar with the potential uses and pitfalls of Gd-EOB-DTPA, which extends beyond the assessment of focal hepatic lesions. The purpose of this article is to review the various usages of Gd-EOB-DTPA in hepatobiliary MR imaging.

show abstract

Modern surgery for liver metastases

Cited by 10 publications

References 30 publications

Liver metastases of colorectal cancer: US, CT or MR?

Liver metastases of colorectal cancer: US, CT or MR?

Ultrasound Examination in Detection and Characterization of Colorectal Liver Metastases

Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging

Contact Info

Product

Resources

About